文献速递神经核医学

采用生物数学建模方法预测淀粉样蛋白PET显像中的临床SUV比值以促进放射性配体的高效开发

Prediction of the Clinical SUV Ratio in Amyloid PET Imaging Using a Biomathematic Modeling Approach Toward the Efficient Development of a Radioligand.
PubMed 文献 · J Nucl Med · 2017-01-06

研究纳入10种临床应用的淀粉样蛋白PET示踪剂,用简化的单组织室模型和生物数学建模预测K1、k2、BPND及SUVR,并与临床观测值比较。预测与临床SUVR的回归关系为y=2.73x-2.11(R2=0.72),作者认为该方法在10种示踪剂中显示预测与临床SUVR相关性良好。

要点

  • 预测与临床SUVR回归关系为y=2.73x-2.11(R2=0.72),涵盖10种临床淀粉样蛋白示踪剂。
  • 预测与临床K1的R2在健康组为0.73、AD组为0.71,k2为0.81和0.85,AD组BPND为0.63。
  • 方法基于简化单组织室模型与生物数学建模,密度固定为3 nM(健康对照)和50 nM(重度AD)。

核心结论

  • 所提出的方法在10种临床应用的淀粉样蛋白示踪剂中显示预测SUVR与临床SUVR相关性良好。

研究设计与样本

  • 研究纳入10种临床应用的淀粉样蛋白PET放射性配体:11C-Pittsburgh compound B、11C-BF-227、11C-AZD2184、11C-SB-13、18F-FACT、18F-florbetapir、18F-florbetaben、18F-flutemetamol、18F-FDDNP和18F-AZD4694。
  • 对每种示踪剂,用简化的单组织室模型结合动脉血浆输入函数和预测的动力学参数生成靶区与参考区的时间-活性曲线。
  • K1、k2和BPND由亲脂性(logP)、表观体积、血浆游离分数、组织游离分数、解离常数和淀粉样蛋白β密度通过生物数学建模推导,密度固定为3 nM代表健康对照、50 nM代表重度阿尔茨海默病(AD)。
  • 预测SUVR通过靶区时间-活性曲线积分除以参考区时间-活性曲线积分获得,并将健康组和AD组的预测K1、k2、BPND及SUVR与各自临床观测值比较以验证方法。

主要发现

  • 预测与临床动力学参数的相关性:健康组K1的R2为0.73,AD组K1的R2为0.71,健康组k2的R2为0.81,AD组k2的R2为0.85,AD组BPND的R2为0.63。
  • 健康组和AD组预测SUVR(y)与临床SUVR(x)的回归关系为y=2.73x-2.11(R2=0.72)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our study aimed to develop a method to mathematically predict the kinetic parameters K1 (influx rate constant), k2 (efflux rate constant), and BPND (nondisplaceable binding potential) of amyloid PET tracers and obtain SUV ratios (SUVRs) from predicted time-activity curves of target and reference regions. Methods: We investigated 10 clinically applied amyloid PET radioligands: 11C-Pittsburgh compound B, 11C-BF-227, 11C-AZD2184, 11C-SB-13, 18F-FACT, 18F-florbetapir, 18F-florbetaben, 18F-flutemetamol, 18F-FDDNP, and 18F-AZD4694. For each tracer, time-activity curves of both target and reference regions were generated using a simplified 1-tissue-compartment model, with an arterial plasma input function and the predicted kinetic parameters. K1, k2, and BPND were derived from the lipophilicity (logP), apparent volume, free fraction in plasma, free fraction in tissue, dissociation constant, and density of amyloid β using biomathematic modeling. Density was fixed at 3 nM to represent healthy control conditions and 50 nM to represent severe Alzheimer disease (AD). Predicted SUVRs for the healthy and AD groups were then obtained by dividing the integrated time-activity curve of the target region by that of the reference region. To validate the presented method, the predicted K1, k2, BPND, and SUVR for the healthy and AD groups were compared with the respective clinically observed values. Results: The correlation between predicted and clinical kinetic parameters had an R2 value of 0.73 for K1 in the healthy group, 0.71 for K1 in the AD group, 0.81 for k2 in the healthy group, 0.85 for k2 in the AD group, and 0.63 for BPND in the AD group. The regression relationship between the predicted SUVR (y) and the clinical SUVR (x) for the healthy and the AD groups was y = 2.73x - 2.11 (R2 = 0.72). Conclusion: The proposed method showed a good correlation between predicted and clinical SUVR for the 10 clinically applied amyloid tracers.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Arakawa Y, Nai Y, Shidahara M, et al. Prediction of the Clinical SUV Ratio in Amyloid PET Imaging Using a Biomathematic Modeling Approach Toward the Efficient Development of a Radioligand. J Nucl Med. 2017. PMID: 28062596. doi:10.2967/jnumed.116.183566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。